Visit https://www.peervoice.com/ATJ860 to view the entire programme with slides. After completing “Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist”, participants will be able to: Discuss the rationale for MET biomarker testing in patients with non–small-cell lung cancer (NSCLC); Describe current testing modalities for patients with NSCLC and recent advances in identifying novel mutations; and Apply MET biomarker testing as standard of care for patients with NSCLC.